MIRA INFORM REPORT

Report Date :

24.12.2014

IDENTIFICATION DETAILS

Name :	ASTELLAS IRELAND CO. LTD.

Formerly Known as :	YAMANOUCHI IRELAND CO. LIMITED

Registered Office :	Damastown Road, Damastown Industrial Park, Mulhuddart 999930

Country :	Ireland

Date of Incorporation :	23.01.1986

Com. Reg. No.:	Ie111917

Legal Form :	Private Company

Line of Business :	· Engaged in manufacturing Three Bulk Active Pharmaceutical ingredients supplied to the Global Market, namely, Famotidine, Solifenacin and Tamsulosin.* · Engaged in Manufacturing a range of treatments, including the Immunosuppressant Prograf^® which is supplied globally from Killorglin Subject Product ranges includes: · Advagraf® (Tacrolimus Monohydrate) · Affex® (Fluoxetine Hydrochloride) · Betmiga™ (Mirabegron) · Difene® (Diclofenac Sodium) · Dificlir™ (Fidaxomicin) · Eligard® (Leuprorelin Acetate) · Locoid® (Hydrocortisone 17-Butyrate) · Modigraf® (Tacrolimus Monohydrate) · Mycamine® (Micafungin Hydrochloride) · Nivadil® (Nilvadipine) · Omnexel® (Tamsulosin Hydrochloride) · Prograf® (Tacrolimus Monohydrate) · Protopic® (Tacrolimus Monohydrate) · Qutenza™ (Capsaicin) · Ulcid® (Omeprazole) · Vesitirim™ (Solifenacin Succinate) · Zepholin S.R® (Theophylline) · Zineryt® (Erythromycin, Zinc Acetate)

No of Employees :	Not Available [We tried to confirm the number of employees but no one is ready to part any information from the company management.]

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security

Status :	Moderate
Payment Behaviour :	No Complaints
Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – September 30, 2014

Country Name

Previous Rating

(30.06.2014)

Current Rating

(30.09.2014)

Ireland

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Ireland ECONOMIC OVERVIEW

Ireland is a small, modern, trade-dependent economy. Ireland was among the initial group of 12 EU nations that began circulating the euro on 1 January 2002. GDP growth averaged 6% in 1995-2007, but economic activity has dropped sharply since the onset of the world financial crisis. Ireland entered into a recession in 2008 for the first time in more than a decade, with the subsequent collapse of its domestic property market and construction industry. Property prices rose more rapidly in Ireland in the decade up to 2007 than in any other developed economy. Since their 2007 peak, average house prices have fallen 47%. In the wake of the collapse of the construction sector and the downturn in consumer spending and business investment, the export sector, dominated by foreign multinationals, has become an even more important component of Ireland's economy. Agriculture, once the most important sector, is now dwarfed by industry and services. In 2008 the former COWEN government moved to guarantee all bank deposits, recapitalize the banking system, and establish partly-public venture capital funds in response to the country's economic downturn. In 2009, in continued efforts to stabilize the banking sector, the Irish Government established the National Asset Management Agency (NAMA) to acquire problem commercial property and development loans from Irish banks. Faced with sharply reduced revenues and a burgeoning budget deficit, the Irish Government introduced the first in a series of draconian budgets in 2009. In addition to across-the-board cuts in spending, the 2009 budget included wage reductions for all public servants. These measures were not sufficient to stabilize Ireland’s public finances. In 2010, the budget deficit reached 32.4% of GDP - the world's largest deficit, as a percentage of GDP - because of additional government support for the country’s deeply troubled banking sector. In late 2010, the former COWEN government agreed to a $92 billion loan package from the EU and IMF to help Dublin recapitalize Ireland’s fragile banking sector and avoid defaulting on its sovereign debt. Since entering office in March 2011, the new KENNY government has intensified austerity measures to try to meet the deficit targets under Ireland's EU-IMF program. Ireland has grown slowly since 2011, but managed to reduce the budget deficit to 7.2% of GDP in 2013. In late 2013, Ireland formally exited its EU-IMF bailout program, benefiting from its strict adherence to deficit-reduction targets and success in refinancing a large amount of banking-related debt.

Source : CIA

Company name & address

Company Name: ASTELLAS IRELAND CO., LIMITED

Company No: IE111917

Company Status: Section 17 (Southern Ireland)

Registered Address: DAMASTOWN ROAD

DAMASTOWN INDUSTRIAL PARK

MULHUDDART 999930

Company Summary

Registered Address DAMASTOWN ROAD

DAMASTOWN INDUSTRIAL

PARK

MULHUDDART

999930

Trading Address DAMASTOWN ROAD

DAMASTOWN INDUSTRIAL

PARK

MULHUDDART

DUBLIN 15

999930

Website Address http://www.astellas.ie

Telephone Number ---

Fax Number ----

TPS No

FPS No

Incorporation Date 23/01/1986

Previous Name YAMANOUCHI IRELAND CO.

Type Private company

FTSE Index -

Date of Change -

Filing Date of Accounts -

Currency USD

Share Capital €4,500,000

Principal Activity

· Engaged in manufacturing Three Bulk Active Pharmaceutical ingredients supplied to the Global Market, namely, Famotidine*, Solifenacin and Tamsulosin.

· Engaged in Manufacturing a range of treatments, including the Immunosuppressant Prograf^® which is supplied globally from Killorglin

Product Description

· Advagraf® (Tacrolimus Monohydrate)

· Affex® (Fluoxetine Hydrochloride)

· Betmiga™ (Mirabegron)

· Difene® (Diclofenac Sodium)

· Dificlir™ (Fidaxomicin)

· Eligard® (Leuprorelin Acetate)

· Locoid® (Hydrocortisone 17-Butyrate)

· Modigraf® (Tacrolimus Monohydrate)

· Mycamine® (Micafungin Hydrochloride)

· Nivadil® (Nilvadipine)

· Omnexel® (Tamsulosin Hydrochloride)

· Prograf® (Tacrolimus Monohydrate)

· Protopic® (Tacrolimus Monohydrate)

· Qutenza™ (Capsaicin)

· Ulcid® (Omeprazole)

· Vesitirim™ (Solifenacin Succinate)

· Zepholin S.R® (Theophylline)

· Zineryt® (Erythromycin, Zinc Acetate)

Current Directors

Name GEAROID PAUL WALSH Date of Birth 27/04/1964